Patents

Wavelengths
Wavelengths

ANEUVO has made significant investments in the development and advancement of its technology platform, with a strong focus on innovation and continuous improvement. Protecting these innovations is a key priority, and patents play an important role in enabling ANEUVO to safeguard its intellectual property while continuing to enhance and expand its offerings.

In accordance with the America Invents Act, this page provides notice of patent protection for certain products. The products listed may be covered by one or more issued patents or pending patent applications in the United States and other jurisdictions.

Product Name US Patent # REF #
ExaStim® Stimulation System
US9,421,369
US20190355476A1
US11715566B2
US12119120B2
US11857783B2
US12167918B2
EXA-001
EXA-011
EXA90002
EXA91002
ExaStim® Portable Stimulator
US9,421,369
US20190355476A1
US11715566B2
US12119120B2
US11857783B2
US12167918B2
BOX-003
BOX90001
BOX91001
ReCure® Electrode Pad
US20190355476A1
US11857783B2
US12167918B2
PAD-003
81100

ANEUVO in the News

ANEUVO has been featured by leading news networks, business and health podcasts, and science and research conferences around the world. Learn more about our company, our technology, and individuals’ experiences with transcutaneous spinal stimulation and the ExaStim® Stimulation System in the stories below.

ANEUVO Receives FDA Clearance for ExaStim<sup><sup>®</sup></sup>

ANEUVO Receives FDA Clearance for ExaStim®

U.S. market entry furthers global mission for accessible clinical and at-home non-invasive neuromodulation therapy Los Angeles, CA, April 16, 2026 (GLOBE NEWSWIRE) -- ANEUVO, a...

Read more
Investigational therapy helps Easthampton man regain movement after spinal cord injury

Investigational therapy helps Easthampton man regain movement after spinal cord injury

EASTHAMPTON, MA (WGGB/WSHM) -- Nearly a decade after a training ride crash left him with a spinal cord injury, an Easthampton man is regaining function...

Read more
ANEUVO Secures Series C Funding to Strengthen ExaStim<sup>®</sup> Regulatory Readiness and Global Operational Scale

ANEUVO Secures Series C Funding to Strengthen ExaStim® Regulatory Readiness and Global Operational Scale

Proceeds to support manufacturing growth, regulatory advancement, and disciplined commercialization expansion Los Angeles, CA, March 05, 2026 (GLOBE NEWSWIRE) -- ANEUVO, a medical technology company...

Read more
ANEUVO Recognized with Taiwan’s 22nd National Innovation Award for ExaStim<sup>®</sup> Neuromodulation Technology

ANEUVO Recognized with Taiwan’s 22nd National Innovation Award for ExaStim® Neuromodulation Technology

Honor highlights international startup advancing non-invasive rehabilitation technology for people living with chronic spinal cord injury Los Angeles, CA, Feb. 11, 2026 (GLOBE NEWSWIRE) --...

Read more
ANEUVO Showcases ExaStim<sup>®</sup> Therapy At RehaCare 2025 and ISCoS 2025

ANEUVO Showcases ExaStim® Therapy At RehaCare 2025 and ISCoS 2025

The first MDR-Approved Non-Invasive Spinal Stimulation System in Europe Los Angeles, CA, Sept. 16, 2025 (GLOBE NEWSWIRE) -- ANEUVO today announced its participation in two...

Read more
ANEUVO’s ExaStim<sup>®</sup> Earns CE Mark Certification

ANEUVO’s ExaStim® Earns CE Mark Certification

Key Milestone Signals Readiness for European Market Entry and Commitment to Quality Los Angeles, CA, April 09, 2025 (GLOBE NEWSWIRE) -- ANEUVO, a pioneer in...

Read more
ANEUVO Launches ASPIRE<sup>™</sup> Home Study to Evaluate Home Use of ExaStim<sup>®</sup>

ANEUVO Launches ASPIRE Home Study to Evaluate Home Use of ExaStim®

This new phase of clinical research will test the safety and feasibility of ANEUVO’s non-invasive therapy for future use by individuals living with chronic spinal...

Read more
Massachusetts skier faces uphill climb after ‘worst possible injury imaginable’

Massachusetts skier faces uphill climb after ‘worst possible injury imaginable’

BOSTON — Michael Feinberg has had three years to think about the moment on the ski slope that changed his life forever. “It’s horrifying,” he...

Read more